Managing All the Genotypic Knowledge: Approach to a Septic Patient Colonized by Different
            <i>Enterobacteriales</i>
            with Unique Carbapenemases

Park, Stacy C.; Wailan, Alexander M.; Barry, Katie E.; Vegesana, Kasi; Carroll, Joanne; Mathers, Amy J; Miller, William R.; Munita, José M.

doi:10.1128/aac.00029-19

Cited by 6 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patient was clinically stable for 5 months with no signs of infection recurrence but died suddenly 6 months after discharge Jacobs 2016 [ 80 ] 47-year-old female kidney transplant recipient; admitted to ICU with post-transplant complications; abdominal abscess and CRKP bacteraemia developed on day 6; CRRT initiated due to AKI secondary to sepsis Yes CRKP 2.5 g q8h (4-h extended infusions), 32 days Bacteraemia was cleared after femoral line exchange. Patient died on day 37 post-surgery Park 2019 [ 82 ] 35-year-old male with cirrhosis, colonised with both blaKPC- and blaOXA-48-carrying organisms; intubated and undergoing CRRT Yes Raoultella planticola (OXA-48) 2.5 g q8h for 14 days Blood cultures on hospital Days 21 and 26 were negative. His treatment course was complicated by another MICU readmission for intubation and CRRT due to worsening kidney injury and respiratory failure.…”

Section: Resultsmentioning

confidence: 99%

Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review

et al. 2021

View full text Add to dashboard Cite

Introduction A systematic literature review was undertaken to evaluate real-world use of ceftazidime-avibactam for infections due to aerobic Gram-negative organisms in adults with limited treatment options. Methods Literature searches retrieved peer-reviewed publications and abstracts from major international infectious disease congresses from January 2015 to February 2021. Results were screened using pre-defined criteria to limit the dataset to relevant publications (notable exclusions were paediatric data and outcomes data for bacteria intrinsically resistant to ceftazidime-avibactam). Data for included publications were subjected to qualitative synthesis. Results Seventy-three relevant publications (62 peer-reviewed articles; 10 abstracts) comprising 1926 patients treated with ceftazidime-avibactam (either alone or combined with other antimicrobials) and 1114 comparator/control patients were identified. All patients were hospitalised for serious illness and most had multiple comorbidities. The most common infections were pneumonia, bacteraemia, and skin/soft tissue, urinary tract, or abdominal infections; smaller numbers of patients with meningitis, febrile neutropenia, osteomyelitis, and cystic fibrosis were also included. Carbapenem-resistant or carbapenemase-producing Enterobacterales (CRE; n = 1718) and carbapenem-resistant, multidrug-resistant (MDR), and extensively drug-resistant Pseudomonas aeruginosa ( n = 150) were the most common pathogens. Most publications reported positive outcomes for ceftazidime-avibactam treatment (clinical success rates ranged from 45 to 100% and reported 30-day mortality from 0 to 63%), which were statistically superior versus comparators in some studies. ceftazidime-avibactam resistance emergence occurred infrequently and mostly in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains. Conclusion This review provides qualitative evidence of successful use of ceftazidime-avibactam for the treatment of hospitalised patients with CRE and MDR P. aeruginosa infections with limited treatment options. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-021-00507-6.

show abstract

Section: Resultsmentioning

confidence: 99%

Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Like K. pneumoniae and other Klebsiella species, a variety of acquired genes have been reported to confer resistance to antimicrobials in environmental and clinical isolates of Raoultella spp., including genes encoding for class A, B, and D carbapenemases. Furthermore, the coexpression of different carbapenemases, such as KPC with IMP or NDM, as well as in combination with OXA-48 has been described (35,(49)(50)(51)(52)(53). Recently, R. ornithinolytica harboring mcr genes have been described (54,55).…”

Section: Antimicrobial Therapymentioning

confidence: 99%

Microbiological and Clinical Aspects of Raoultella spp.

Appel

Quijano-Martínez

Cadena

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

The genus Raoultella was established in 2001. Species of Raoultella and Klebsiella share many ecological, biochemical, clinical, and microbiological features. Given the shortcomings of available technology for species identification in the clinical microbiology laboratory, are practically indistinguishable. Since the late 2000s there has been an increase in case reports of human Raoultella infections. Therefore, several authors are postulating that Raoultella spp. are rare and/or emerging pathogens.Conclusions:Raoultella spp. are very similar to Klebsiella spp. The epidemiology and the clinical relevance of the human Raoultella spp. infections is uncertain and further studies are required. The previous difficulties in the identification of Raoultella spp. and the introduction of more precise identification techniques may explain the recent increase in the number of case reports. Raoultella spp. might be rather underdiagnosed than rare or emerging pathogens.

show abstract

Emergence of blaNDM-1, blaNDM-5, blaKPC-2 and blaIMP-4 carrying plasmids in Raoultella spp. in the environment

Zou

Berglund

Wang

et al. 2022

Environmental Pollution

View full text Add to dashboard Cite

Managing All the Genotypic Knowledge: Approach to a Septic Patient Colonized by Different Enterobacteriales with Unique Carbapenemases

Cited by 6 publications

References 22 publications

Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review

Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review

Microbiological and Clinical Aspects of Raoultella spp.

Emergence of blaNDM-1, blaNDM-5, blaKPC-2 and blaIMP-4 carrying plasmids in Raoultella spp. in the environment

Contact Info

Product

Resources

About